Fred Alger Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Fred Alger Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8,000	Closed	-$179K	–	578
2019 Q1	$179K	Buy	8,000 +4,500	+129%	+$96.7K	﹤0.01%	398
2018 Q4	$64K	Sell	3,500 -10,500	-75%	-$165K	﹤0.01%	391
2018 Q3	$253K	Hold	14,000	–	–	﹤0.01%	382
2018 Q2	$139K	Hold	14,000	–	–	﹤0.01%	388
2018 Q1	$74K	Sell	14,000 -3,000	-18%	-$21.4K	﹤0.01%	415
2017 Q4	$145K	Sell	17,000 -13,000	-43%	-$160K	﹤0.01%	407
2017 Q3	$438K	Sell	30,000 -3,000	-9%	-$45.4K	﹤0.01%	359
2017 Q2	$618K	Buy	33,000 +15,000	+83%	+$338K	﹤0.01%	356
2017 Q1	$383K	Buy	18,000 +3,346	+23%	+$64K	﹤0.01%	370
2016 Q4	$223K	Buy	+14,654	New	+$199K	﹤0.01%	347

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Fred Alger Management's RARX Position: Q2 2019 in Review

Fred Alger Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 8,000 shares — an estimated $179K sold.

Fred Alger Management first reported a position in RARX in Q4 2016 and held it in 10 quarters. The position peaked at $618K in Q2 2017. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

Fred Alger Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Fred Alger Management sold 8,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $179K.
Fred Alger Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 10 quarters.
Fred Alger Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $618K in Q2 2017.
118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Fred Alger Management's 13F filing for Q2 2019, filed 14 Aug 2019.